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Abbreviations:
Alpha (α)

initial half-life in a two compartment model, usually representing
distribution

AUC

area under the curve

Beta (β)

second decay half-life in a two compartment model, usually representing
elimination

Ce

cerium

CL

clearance

Cmax

maximum concentration

ENM

engineered nanomaterial

iv

intravenous

ICP-MS

inductively coupled plasma mass spectrometry

MDL

method detection limit

MRT

mean residence time

PBPK

physiologically-based pharmacokinetic

t½

half-life

Vdss

apparent volume of distribution at steady state

Abstract:
Objectives: Characterize different sized ceria engineered nanomaterial (ENM)
distribution in and clearance from blood, compared to the cerium ion, following
intravenous infusion. Methods: Cerium (Ce) was quantified in whole blood, serum, and
clot (the formed elements) up to 720 h. Results: Traditional pharmacokinetic modeling
showed best fit for 5-nm ceria ENM and the cerium ion. Ceria ENMs larger than 5 nm
were rapidly cleared from blood. After initially declining, whole blood 15- and 30-nm
ceria increased; results not well-described by traditional pharmacokinetic modeling. The
cerium ion and 5- and 55-nm ceria did not preferentially distribute into serum or clot, a
mixture was predominantly in the clot, and 15- and 30-nm ceria migrated into the clot
over 4 h. Conclusions: Five-nm ceria may not be readily recognized by
reticuloendothelial organs. Increased ceria distribution into the clot over time may be
due to opsonization. Traditional pharmacokinetic analysis was not very informative.
Ceria ENM pharmacokinetics are quite different from the cerium ion.

Key words:
blood, ceria, distribution in blood, engineered nanomaterial, half-life, pharmacokinetics,
systemic clearance

Future perspective:
Current uncertainties in nanoscale material evaluation in biological systems include
proper/adequate material characterization, the dose metric(s) that best describe and
predict their effects, and whether they behave like traditional xenobiotics. A key
component of research quality and standardization with nanoscale materials is their
physicochemical characterization. The “appropriate” characterization methods are
currently under intense debate, as is the “best” metric of dose or exposure. Further
research results that identify the material characterization methods most relevant to
their biological properties and dose metrics that best predict ENM response will guide
researchers toward more standard and appropriate methods, increase confidence in the
results, and generate more consistent results. This is occurring and is expected to
mature in the next 5 to 10 years.

The ongoing generation of research results by many groups describing the kinetics of
ENMs will provide much more insight into how ENMs are handled in vivo. The kinetic
endpoints include absorption (uptake), distribution, biotransformation (and
opsonization), re-distribution (translocation), and elimination. These appear to be greatly
influenced by the physicochemical properties of nanoscale materials. As noted in a
recent review of the pharmacokinetics of carbon-based and quantum dot ENMs, they
are not amenable to classical pharmacokinetic parameter estimations due to their
differences from the solution chemistry of their components. Results of the present work
support this observation, leading to the necessity to adopt or develop other approaches
to describe ENM pharmacokinetics. It is anticipated that this will occur over the next 5

to10 years, perhaps utilizing predictive, pharmacokinetic, physiologically-based, or nontraditional modeling approaches. This study illustrates the necessity of developing such
models.

Executive summary:
•

Nanoscale ceria pharmacokinetics, biodistribution, and clearance pattern cannot
be predicted from those of the cerium ion.

•

Nanoscale ceria circulation time in the blood of particles too large to be filtered by
the kidney (> 5 nm) and apparently too small to be readily recognized by the
reticuloendothelial organs (< 15 nm) is much longer than larger nanoscale ceria.

•

Cubic and polyhedral nanoscale ceria that was 15 nm or greater in diameter was
very rapidly cleared from circulating blood. The small remaining fraction in blood
persisted for some time.

•

Nanoscale ceria size and shape influenced its distribution between blood serum
compared to a blood fraction containing red cells, white cells, and platelets.

•

The results suggest nanoscale ceria undergoes surface chemistry changes in
blood within hours of its entry, and that these changes are most pronounced with
15 to 30 nm ceria particles. This may be due to opsonization.

•

The sites of ceria ENM residence in and outside of circulating blood during the
first several hours after its administration and the physicochemical properties that
influence this are not well understood.

•

A firm understanding of the rate and nature of ceria ENM association with blood
proteins and cells and the process(es) of their clearance from blood are needed
to fully interpret their fate in the vascular compartment.

•

The analysis of nanoscale particle concentration in blood vs. time is not
amenable to traditional pharmacokinetic analyses. This is illustrated by the
increase in cerium in blood after ceria ENM iv infusion; an unusual property

following the iv administration of agents. Non-classical methods are necessary
to model and interpret the pharmacokinetics of ENMs.

Introduction:
There has been much research to develop engineered nanomaterials (ENMs). Polymer
ENMs are being developed as drug delivery systems [1, 2], and some metal and metal
oxide ENMs are being developed as therapeutic agents. Human exposure may also
come from occupational and environmental sources. Little is known about ENM
distribution or persistence in the vascular system. We were unable to find published
studies of the distribution of metal or metal oxide ENMs among blood compartments.

To investigate the persistence and distribution of a model ENM in blood we utilized ceria
(a.k.a.: CeO2, ceric oxide). Numerous studies reported ceria ENM to be neuro- and
cardioprotective, suggesting it has therapeutic utility in medical disorders caused by
reactive oxygen species [3-11]. On the other hand, there are reports of ceria-induced
toxicity associated with increased oxidative stress [12-17]. Nanoscale ceria is a catalyst,
marketed as a diesel fuel additive, generated during combustion in the Eolys® system
[101], and is in the walls of self-cleaning ovens. As an abrasive it is used in chemicalmechanical planarization in electronic circuit manufacture. Nanoscale ceria was
nominated by the U.S. National Institute for Environmental Health Sciences, NIH, for
toxicological consideration, including toxicokinetic studies [102]. The Organisation for
Economic Co-operation and Development Environment Directorate included ceria on its
priority list of nanomaterials in commerce (or likely to enter into commerce in the near
term) for measurement, toxicology and risk assessment [103]. However, there are no
reported studies of the pharmacokinetics of nanoscale ceria other than our report that a
commercial ~ 30-nm ceria had an initial t½ of ~ 0.125 h [18]. It is vitally important to

understand the pharmacokinetics of ENMs in relation to their potential therapeutic
applications and/or toxicity. The pharmacokinetics of carbon-based ENMs and quantum
dots has been reviewed [19], but much less has been reported for other metal and
metal oxide ENMs.

Little is known about the influence of size on the distribution in and clearance from blood
of metal and metal oxide ENMs. We found that the blood cerium concentration was 0.56
and 1.3 mg/L after a 1 h infusion of 50 or 250 mg/kg of an ~ 30-nm commercial ceria
ENM to rats [18]. In contrast, 1 h after infusion of 100 mg/kg of an in-house
manufactured 5-nm ceria ENM it was 370 mg/L [20], suggesting that the rate of metal
oxide ENM clearance from blood was size dependent. The present study was
conducted to test this hypothesis.

Another factor that influences the rate of ENM clearance from blood and their
distribution is their surface chemistry, including charge and surface coating. A zeta
potential greater than +30 or less -30 mV decreases the potential for agglomeration in
the medium due to repulsive electrostatic forces [21]. ENMs are often coated with
polymers such as polyethylene glycol or oxygen-rich ions such as citrate. These coating
increase ENM hydrophilicity and stabilize ENM dispersions through the electrostatic
repulsion mechanism, which may reduce their clearance by the reticuloendothelial
system [22-25]. [Note: do not use the work, solubility, here.]Citrate, an endogenous
molecule present in the blood and an integral component of the tricarboxylic acid cycle,
was used in the present study as a ceria surface coating to minimize agglomeration. It

has been shown that citrate-surface coating of metal/metal oxide ENMs resulted in their
non-specific attachment to the surface of HeLa cells in vitro and over-coating by humic
acid and albumin [24, 26, 27].

The present work was conducted to test the hypotheses that the fate of a metal oxide
ENM in blood is different than its constituent metal and that ENM size and shape
influence its persistence in and distribution within the major components of blood. We iv
infused the cerium ion, four sizes of cubic or polyhedral citrate-coated ceria ENMs, and
a mixture of cubic and rod-shaped ceria to rats. Blood was repeatedly withdrawn up to 4
h later, and in some cases up to 30 days. An aliquot of each blood sample drawn up to
4 h after ceria infusion was allowed to clot. By comparison of Ce in whole blood, serum,
and the clot we could determine pharmacokinetic parameters of ceria distribution in, and
clearance from, blood.

Materials and methods:
Cerium chloride heptahydrate (Sigma-Aldrich #228931, 99.9% metal basis), cerium
nitrate hexahydrate (Sigma-Aldrich # 22350, >99.0%), sodium hydroxide (Fisher #S3181, certified ACS pellets), ammonium hydroxide (Fisher # 3256, ACS, 28-30%),
hexadecyltri-methylammonium bromide (CTAB, Sigma-Aldrich #H9151, ~99.0%),
deionized ultra filtered water (DIUF, Fisher #W2-20), and citric acid monohydrate (EMD
Chemicals Inc # CX1725-1, GR ACS) were used without further purification.

Ceria ENM synthesis
Five nm ceria ENM was synthesized as described [28]. Typically a 20 ml aqueous
mixture of 0.5 M (0.01 mol) ceria chloride and 0.5 M (0.01 mol) citric acid was added to
20 ml of 3 M ammonium hydroxide. The latter was in excess of that needed for
complete reaction of the cerium chloride to cerium hydroxide. The final product was an
un-buffered ceria dispersion with a pH of 8 to 9. After stirring for 24 h at 50°C, the
solution was transferred into a Teflon-lined stainless steel bomb and heated at 80°C for
24 h to complete the reaction. The cerium concentration in samples taken from the top
and bottom of two ceria dispersion samples that were un-disturbed for > 2 months were
within 2.5% of each other, demonstrating dispersion stability. Settling of the 5 nm ceria
dispersion was not observed over at least three months and dynamic light scattering
estimates of 5 nm ceria particle size distributions were similar to those obtained initially.
The dispersed ceria ENM was infused intravenously without any further treatment.

Fifteen nm ceria ENM was synthesized using a hydrothermal procedure [29]. In a typical
procedure, 2 ml ammonium hydroxide was drop-wise added into 20 ml aqueous mixture
of 1.5 mmol cerium nitrate and 0.5 mmol CTAB and kept stirring for 0.5 h to form a
brown emulsion. The emulsion was transferred into a Teflon-lined stainless steel bomb
and heated at 120 °C for 24 h to complete the reaction. The fresh product was washed
with water three times to remove free cerium, dialyzed three times with fresh citric acid
aqueous solution, and dried at 55 °C for 24h. The final 15 nm citrate modified ceria
powder was re-dispersed into water to prepare a ~5 wt% aqueous suspension. The pH
of the resulting un-buffered ceria dispersion was 3.5.

Thirty nm ceria was synthesized using a hydrothermal approach [30]. Generally, 20 ml
aqueous mixture of 1 mmol cerium nitrate and 105 mmol sodium hydroxide was stirred
for 0.5 h to get a milky suspension. The suspension was transferred into a Teflon-lined
stainless steel bomb and heated at 180 °C for 24 h. After the hydrothermal treatment,
fresh white precipitates were washed with deionized water three times and then ethanol
three times to remove the free cerium and organic impurities. Then the wet precipitates
were dispersed into 0.05 M citric acid aqueous solution with stirring overnight, followed
by washing with water 5 times. The resulting dispersion had a pH of 3.9.

The mixture of 30 nm cubic ceria ENMs with nanorods was synthesized using a
hydrothermal method [31]. Typically, 0.9 mmol cerium nitrate was dissolved into 15 ml 9
M sodium hydroxide solution with stirring for 0.5 h. The suspension was transferred into

a Teflon-lined stainless steel bomb and heated at 140 °C for 48 h. After the
hydrothermal treatment, fresh precipitates were separated by centrifugation, and
washed with deionized water three times. The wet precipitates were dispersed into 0.06
M citric acid aqueous solution overnight, washed with water for several times until the
final suspension had a pH around 7.

Fifty-five nm ceria ENM was synthesized by a method [32] modified with controlled
thermal treatment to achieve the desired ceria particle size (unpublished results). It was
re-dispersed in citrate solution and washed three times in doubly distilled water to
remove free cerium and citrate. The resulting dispersion had a pH of 7.

Ceria characterization
The morphology, crystallinity, and phase purity of each citrate-coated ceria ENM were
determined in our laboratories using high resolution-transmission electron
microscopy/scanning transmission electron microscopy and X–ray diffraction analyses.
Primary particle size distributions were determined by TEM analysis [33]. The
crystallinity of all ceria ENMs were determined by XRD (Siemens 5000 diffractometer).
Particle size distributions in aqueous suspension were determined using dynamic light
scattering (90Plus Nanoparticle Size Distribution Analyzer, Brookhaven Instruments
Corp, Holtsville, NY). To indicate the stability of the ceria dispersion when infused into
the rat, the zeta potential was measured for each ENM (except the mixture of ceria
nanoparticles and nanorods) using a Zetasizer nano ZS (Malvern Instruments,
Worchestershire, UK). The Zetasizer estimates the surface charge of nanoparticles

based on the assumption that the correlations are generated from spheres, but
nanorods have an elongated axis and different mobility from spherical nanoparticles; the
instrument therefore often fails to provide consistent and accurate estimation for
nanorods and mixtures that include rods. Since all of the ceria ENMs had hydrodynamic
diameters < 200 nm, the Hückel approximation was used to calculate zeta potential
from electrophoretic mobility. To estimate the extent of citrate surface coating each of
the ceria ENMs was washed at least three times with water before drying. As separation
of the 5 nm ceria by centrifugation required ~12000 rpm for 12 h due to their small size,
they were agglomerated by decreasing the pH to 4, enabling centrifugation.
Thermogravimetric analysis (Perkin-Elmer TGA7 Analyzer) was then performed to
investigate the weight loss of citrate-coated ceria NPs over the temperature range of
150 to 300°C under which decomposition of citric acid occurs. The extent of citrate
surface coating was estimated based on the assumption that all the ceria NPs were
spherical and had uniform size. The free cerium concentration in the ceria dispersions
of the unwashed 5 nm ceria and each of the washed ENMs was determined using
Amicon Ultra-4 centrifugal 3000 molecular weight cut-off filter devices and centrifugation
at 3000 g to obtain filtrate, which was analyzed for cerium by ICP-MS.

Animals
Data were obtained from 101 male Sprague Dawley rats, weighing 325 ± 30 g (mean ±
SD), that were housed individually in the University of Kentucky Division of Laboratory
Animal Resources facility. All animal studies were approved by the University of
Kentucky Institutional Animal Care and Use Committee. The research was conducted in

accordance with the Society of Toxicology’s Guiding Principles in the Use of Animals in
Toxicology (http://www.toxicology.org/ai/air/air6.asp).

Cerium ion and ceria ENM administration
Rats were prepared with 2 cannulae, surgically inserted into femoral veins under
ketamine/xylazine anesthesia, which terminated in the vena cava, and were connected
to infusion pumps via a flow-through swivel. This enabled conduct of the study in the
awake, mobile rat. All samples were sonicated to ensure dispersion prior to
administration. The day after cannulae implantation the un-anesthetized rat was infused
via the longer cannula with cerium ion (as the chloride), a ~ 5% ENM dispersion in
water, or water. A pilot study was conducted with the cerium ion and each of the ceria
ENMs to determine tolerability following iv infusion. A 100 mg cerium ion/kg infusion
was lethal. Rats were infused with ~250 or 175 mg/kg of the 5 nm ceria; 3 of 8 died. A
dose of ~250 mg of the 15 nm ceria/kg was tolerated. Infusion of 100 mg/kg of the 30
nm ceria resulted in some evidence of mild distress (tachypnea, skittish behavior, and
not resting well). Dyspnea and lethargic were seen in rats given 250, 100 or 78 mg of
the 55 nm ceria/kg. Therefore the target doses were 100 mg/kg for the 5, 15, and 30 nm
ceria and 50 mg/kg for the 55 nm ceria ENM and the cerium ion. ICP-MS analysis of
cerium in replicate samples of the dosed materials showed the doses to be 70 to 100%
of the target doses. Each was infused over 1 h, except for the cerium ion that was
infused over 2 h. Control rats received water adjusted to the pH of the paired ceria ENM
or cerium ion. To compensate for the iv administration of a considerable volume of
grossly hypotonic infusion, concurrent iv infusion of an equal volume and rate of 1.8%

sodium chloride in water was delivered into the second, shorter, cannula. Each fluid was
delivered at ~ 0.6 ml/h.

Sample collection
After the infusion, 0.6 ml blood was withdrawn at 0.167, 0.5, 0.75, 1, 2 and 4 h from the
cannula that had not delivered ceria from 3 rats that had received infusion of the cerium
ion, 6 that received the 30 nm ceria ENM, and 5 that received the 5, 15, 55 or 30 nm
ceria cube + rod ENM. The blood sample was immediately separated volumetrically into
two 0.3 ml aliquots to enable determination of Ce in whole blood in one and in the
serum and clot fractions of the other. A blood clot is formed by platelets and blood
proteins, including fibrin, and traps the blood’s red and white cells. It may have some
serum trapped in it; therefore the clot fraction may over-estimate the percentage of Ce
associated with cells. To determine the distribution of Ce in the serum and clot fractions
the 0.3 ml sample of whole blood was allowed to clot at room temperature, the clot
given time to contract, and serum withdrawn into a digestion vessel. The clot was
withdrawn and placed in another digestion vessel and the remaining serum added to the
serum sample. This enabled determination of the mass amount of Ce in the two major
compartments of blood; serum and, from the clot fraction, association with the formed
elements (red cells, white cells and platelets). This approach was taken to avoid
centrifugation to generate the serum sample because we found that centrifugation at
1600 g for 10 min, as used to generate serum, resulted in loss of ~ 75% of a 30-nm
ceria ENM from the serum sample [18].

Blood was also obtained from some rats 20, 168 (1 week) or 720 h (1 month) after ceria
ENM administration. An equal volume of saline was infused after each blood
withdrawal to replace the fluid volume. Blood was obtained at termination of all rats.

Cerium analysis:
To determine Ce in whole blood the sample was transferred into a 55 ml TFM
(polytetrafluoroethylene) digestion vessel (CEM) to which 6 ml trace-metal grade nitric
acid and 3 ml 30% H2O2 were added, digested in a CEM MARS Xpress microwave at
180 °C for 10 min to convert all ceria to dissolved Ce4+, diluted with 18 MΩ water to 50
ml, and subsequently further diluted dependent on the Ce concentration.
Cerium concentration was determined in whole blood, serum and clot by ICP-MS
(Agilent 7500cx, Santa Clara, CA, U.S.). Following ceria ENM administration, Ce
concentration is believed to reflect the Ce in ceria ENM because ceria ENMs are quite
inert and persist as an ENM in the rat for months [34], and the Ce levels in non-Ce
treated rats is very low. We determined a method detection limit (MDL) of Ce for blood
and serum samples of 0.018 mg/L [18]. No samples in this study had Ce concentrations
below this MDL. Seven samples, containing whole blood, serum or clot, were analyzed
in duplicate and were spiked with 8.3 ng Ce/ml. Results of duplicate analysis showed a
range of 0 to 4% between the two determinations. Recovery of the Ce spike ranged
from 93 to 114%, averaging 105%.

Data analysis and statistics:

Blood, serum and clot Ce concentrations were normalized to an infusion dose of 100
mg ceria/kg for all rats, based on determination of the actual Ce content of the infusions
by ICP-MS analysis, and because a few materials were given at doses other than 100
mg/kg, as noted above. This enabled direct comparison of results from the cerium ion,
ceria ENM sizes, and shapes. Outliers, identified using the Grubbs test, were not
included in the data analysis. Four percent of the 600 whole blood, serum and clot
samples were outliers by this test.

Pharmacokinetic modeling. Non-compartmental and compartmental analyses of the
whole blood Ce concentration vs. time results were conducted using WinNonLin, a
pharmacokinetic analysis program (Pharsight®, St. Louis, Missouri). For noncompartmental analysis, AUC (h*mg/L), Cmax (mg/L), half life (t1/2, h), and mean
residence time (MRT, h) were calculated. The squared correlation of distances (Rsq)
and correlation between time (X) and Ce concentration (Y) (Corr-XY) were used to
measure the goodness of fit. For compartmental analysis, one and two compartments
were evaluated to determine the best model fit. AUC (h*mg/L), Cmax (mg/L), half life (t1/2,
h), mean residence time (MRT, h), clearance (CL, ml/h/kg) and apparent volume of
distribution at steady state (Vdss) were calculated. Various weightings were evaluated,
including 1, 1/y (y: ceria concentration, which weights higher values more heavily), 1/y2
(which weights lower values more heavily), 1/predicted concentration (iterative
reweighting), and 1/predicted concentration2. Goodness of fit was based on visual
inspection, weighted corrected sum of squares, sum of square residuals, weighted sum
of square residuals, random distribution of residuals, Akaike’s information criteria, and
Swartz criteria. The initial estimates for model parameters were calculated as below.

The semi-logarithmic plots of blood concentration vs. time data showed the one or two
compartment kinetics model as C(t) = Re−λt and C(t) = R1e−λ1t + R2e−λ2t , respectively.
𝑅𝑅1 and 𝑅𝑅2 represent intercepts on the concentration (Y) axis of the back-extrapolated

initial and terminal phases and λ1 and λ2 = the initial and terminal slopes. As blood

sampling began after completion of the infusion, the iv bolus case was used.
Divλ

A = k �1−e−λt� R was used to correct the infusion intercept values for the one
ο

Divλ1

Divλ2

compartmental analysis and A1= k �1−e−λ1t� R1 and A2= k �1−e−λ t� R2 were used in the two
ο

ο

2

Div

compartment model. Div is the infusion dose, kο is the infusion rate. V1= A1+A2 was used
to calculate the volume of the central compartment. The micro rate constants were
determined as k21=

λ2×A1+λ1×A2
A1+A2

; k10=

λ2×λ1
K21

; and k12=λ1 + λ2 − k10 − k21. k12 and k21

represent the rate constants between central and peripheral compartment, and k10 is the
elimination rate constant from the central compartment. The elimination half-lives (t1/2)
were calculated as t1/2λ1 =0.693/λ1 and t1/2λ2 =0.693/λ2. One-way ANOVA, followed by

Tukey’s multiple comparison tests (Prism 5.02 software, GraphPad, San Diego, CA),
was used to test for significant differences in pharmacokinetic parameters among the 6
treatment groups.

Quality analysis of the WinNonLin coefficients was conducted by determining whether
the ratio of the coefficient estimate to its average standard error was greater than the
appropriate p value < 0.05, using a two-tailed Student’s t-test (3.18 for n = 3, 2.78 for n
= 4), Excel and Systat. The results showed that the pharmacokinetic parameter
estimations using WinNonLin were acceptable for only the cerium ion and the 5-nm

ceria ENM. Two factors contributing to this were 1) that less than 2% of the dose of the
other 4 ENMs was circulating in the blood when the first sample to estimate the
pharmacokinetic parameters was obtained (0.167 h after completion of the infusion),
and 2) the Ce concentration increased in blood from 0.167 to 4 h after infusion of the
15- and 30-nm ceria, which is not the elimination behavior for typical pharmacokinetic
models. Therefore, the pharmacokinetic data for ceria ENMs was compared directly to
that of the cerium ion, which is known to follow typical pharmacokinetic elimination
models.

Ratio of Ce concentration in whole blood following infusion of ceria ENMs vs. the cerium
ion. The Ce ratio in ceria ENMs compared to the cerium ion was reported as
R=

[Ce]ceria
[Ce]cerium(ion )

R = R 0 ⋅ exp(−α ⋅ t ) met the t-test criterion, then the trend was described by an apparent
first order process.

Ce partitioning between serum and clot. The quality of the data describing the
partitioning of Ce between the serum and clot fractions was screened using mass
balances. The total mass of cerium (or ceria) in the whole blood sample should equal
the sum of the cerium masses in the serum and clot phases. The cut-off for mass
material balance screening was taken to be ± 30%. If the sum of the masses of Ce in
the serum and clot phases was < 70 or > 130% of that in the mass in the whole blood
sample, the partitioning data were not used in the analysis or shown in the figure. No
other screening analyses, such as outlier evaluation, were applied. The partitioning of
cerium was reported as the ratio of cerium in the serum phase to that in whole blood.

Results:
Particle morphologies are shown in Figure 1. Panel D in Figure 1 is part of a larger
image that shows the diameter and length of the rods in the mixture of 30-nm cubic and
rod ENMs were ~ 10 nm and 2 µm, respectively. The shape, surface area, zeta
potential in water, and estimated extent of the ENM surface that was coated with citrate
are shown in Table 1. All of the ceria ENMs had face-centered cubic (FCC) crystal
structures with the same Miller indices of (111), (220) and (311), and with lesser
presence of (200), (222) and (400), based on XRD crystal structure linked to known
morphology. The 55 nm ceria had the lowest surface coating of citrate and a lower
absolute surface charge (-31.5mV) than the other ENMs. The unwashed 5 nm ceria
ENM had 11.6 ± 0.3% free cerium in the dispersion. The washed ceria ENMs were
found to contain << 1% free cerium.
Ten min (0.167 h) after completion of the cerium ion or 5-nm ceria ENM infusion ~ 14
and 32% of the Ce remained in the circulating blood, respectively. This was calculated
from the measured blood Ce concentration compared to the Ce dose, based on the iv
infusion of 100 mg ceria/kg into the rat’s vascular system (~ 7% of its body volume),
which would introduce ~ 1163 mg Ce/l blood. In contrast, the 15-, 30- and 55-nm ceria
and mixture of 30-nm cubic + rod ceria were rapidly removed from circulation, so that
0.167 h after their infusion ≤ 2% was in blood (Figure 2).

Pharmacokinetic models were constructed using whole blood Ce concentrations from
each individual rat’s results. Non-compartmental models showed the best fits for the
cerium ion (Rsq 0.94 ± 0.08, Corr XY = 0.97 ± 0.04) and 5 nm ceria ENM (Rsq 0.89 ±

0.06, Corr XY = 0.94 ± 0.03). However, 15, 30 cubic, 30 cubic + rods, and 55 nm ceria
ENMs were poorly fitted by non-compartmental modelss. One and two compartment
models showed the Ce concentrations in blood obtained 0.167 h to 1 week after cerium
ion infusion and 0.167 h to 30 day following infusion of 5-, 15-, and 30- nm ceria ENMs
were best fit by two compartmental models (biexponential decay). For the mixture of 30nm cubic + rod ceria and the 55-nm ceria ENMs, for which modeling was based on
results to 4 h after their infusion, the one compartment model provided the best fit.

Table 2 summarizes the pharmacokinetic parameters. Compartmental analysis showed
the cerium ion to have a greater AUC than the ceria ENMs, a higher Cmax compared to
the ≥ 15 nm ENMs, and a smaller Vdss than all of the ENMs. Surprisingly, the 15- and
30-nm cubic ceria materials showed increasing blood concentrations over the period 0
to 4 h after infusion, with estimated half-lives of this process of ~ 4 and 2.7 h,
respectively (Figure 2). Since conventional elimination models are always monotonically
decreasing in solute concentration, the WinNonLin fits were poor and the 15 and 30 nm
ceria ENMs model coefficients did not meet the Student’s t-test criteria for quality (the
average standard error was often larger than the estimated value of the coefficient).
With the exception of the 5-nm ceria ENM, the pharmacokinetic results are based on <
2% of ceria dose that was remaining in the blood 0.167 h after completion of the ceria
infusion, therefore the pharmacokinetic parameter estimates describe only a small
fraction of the dose of these ENMs. The two-compartment models for each of the rats
that received cerium ion or 5-nm ceria ENM infusions fit the data very well based on
visual inspection, weighted corrected sum of squares, sum of square residuals,

weighted sum of square residuals, random distribution of residuals, Akaike’s information
criteria, and Swartz criteria.

Figure 3 shows the ratio of the whole blood Ce concentration after infusion of 5-, 15-,
30-, and 55-nm ceria ENMs vs. the cerium ion. The ratio, R, for 5 nm ceria ENM could
d

be modeled either by a power law dependence, R = R0 ⋅ t (R0 is a constant and d is the
power exponent for time t), or an exponential dependence, R = R0 ⋅ exp(d ⋅ t) (R0 is the
Arrhenius-type factor and d is the process rate constant) for each of three animals.
Trend lines are shown for the power law dependence (Figure 3, top panel) with d ~ -0.8.
Five-nm ceria ENMs are fitted by two-compartment models and their concentrations
have apparent links to those of cerium ions, but with different time dependencies. Over
the time period, 0 to 4 h after infusion, it was cleared faster than the free ion. On the
other hand, R values for both 15 and 30 nm ceria increased over the 0 to 4 h time
period and their exponential coefficients were similar (d = 0.41 h-1 and d = 0.45 h-1,
respectively). The R value of 55 nm ceria showed no strong trend.

The Ce mass balance for cerium ion, calculated by comparing the cerium in the serum
plus clot samples to the cerium in whole blood, averaged 98 ± 7% over all samples. For
the 5-nm ceria ENM, the average mass balance was 83 ± 44%; 5 out of the total of 30
values from the 6 sample times were below the cutoff of 70% mass balance. These
ranged from 16 to 31% and were obtained 120 or 240 min after the ceria infusion, at a
time when Ce concentrations had decreased to an average of 8 and 0.4 microgram Ce
in the serum prepared from the 0.3 ml of blood. They were not used in the data

analysis. For the remaining 25 values, recovery was 93 ± 40%. For the 15-, 30-, and 55nm ceria ENMs, 17, 16 and 11 of the 18 values from 3 of the rats met the material
balance quality control criteria and were used in the data analysis, respectively. For the
30-nm ceria cubes and rods mixture, 12 values from 2 rats met the material balance
quality control criteria and were used in the data analysis.

Figure 4 shows the ratio of Ce distribution in blood serum vs. whole blood from 0.167 to
4 h after completion of the cerium ion or ceria ENM infusions. The complement to this is
the ratio of Ce in the clot (associated with the red and white cells and platelets) vs.
whole blood fraction (not shown). The ratio of Ce in serum vs. whole blood shows its
distribution between blood serum and (the clot fraction). Blood samples taken from 0 to
4 h after infusion showed that the cerium ion, 5-, and 55-nm ceria ENMs did not
preferentially distribute into either the blood serum or clot (containing red, white cells
and platelets); there was no consistent time dependence of the ratio for all animals. The
30 nm cubic + rod mixture preferentially distributed to the clot fraction over a similar
period, also with no consistent time dependence of the ratio for all animals. However,
serum/clot partition data for 15- and 30-nm ceria showed that these ENMs migrated into
the clot fraction, and that partition ratio ceria in the clot increased with time. Two of the
rats that received 15 nm and 4 that received 30 nm ceria showed a statistically
significant increase of Ce associated with the clot fraction.

Discussion:
The crystal structure of the ceria ENMs was as expected because the fluorite structure
is the only one for crystalline CeO2. The citrate coating was least dense on the 55 nm
ceria, suggesting it would be the most likely of the ENMs test to agglomerate in
aqueous dispersion; a problem that was observed during its administration requiring
frequent agitation of the dispersion to prevent it from occluding the infusion line.
Although nearly 12% of the total cerium in the 5 nm ceria ENM was free cerium in the
aqueous phase, comparison of the results after infusion of the 5 nm ceria ENM, the
cerium ion, and the other ceria ENMs shows the free cerium cannot account for the
differences between the 5 nm and the larger ENMs.

In the present study ~ 14% of the cerium ion remained in the blood 0.167 h after
completion of a 1 h iv infusion. In a previous report Ce was determined in blood from 1 h
to 3 days following its iv administration as the chloride to mice and rats; however, the
author did not conduct a pharmacokinetic analysis of the results [35]. Using WinNonLin
to conduct pharmacokinetic analysis, non-compartmental and compartmental
calculations of the Bjondahl results [35] showed similar AUC, MRT, Cmax, and CL
results. The non-compartmental half-life (10 h) was the same as the terminal half-life
obtained with a two compartment model, which best fit the data for compartmental
analysis. The initial half-life of the Bjondahl results (~ 3 h) was longer than we obtained
(0.6 h) because our study included samples taken as early as 10 min, whereas the first
sample in the Bjondahl study was obtained at 1 h.

Ten min after completion of the iv infusion of ceria ENMs, ~ 32% of the 5-nm ceria but <
2% of the larger ceria ENMs were present in the blood. The greater extent of citrate
coating on the 5-nm ceria (and therefore its greater hydrophilicity) may have contributed
to this. However, we do not know how long the citrate persisted on the surface of the
ceria ENM or if was covered (opsonized) by proteins. The rapid clearance of
metal/metal oxide ENMs from blood has been reported previously.

Little has been reported about the fate of systemic cerium, other than it is very slowly
eliminated, primarily in bile, resulting in prolonged retention in mammals, primarily in the
liver and skeletal system [36, 37]. Our pharmacokinetic results showed that the cerium
ion had a smaller Vdss than the 5-nm ceria ENM. It also showed less retention in
reticuloendothelial tissues, but more in the lung [34]. All the ceria ENMs showed a large
Vdss indicating great distribution in tissues, consistent with the intracellular
agglomerations we have seen, especially in reticuloendothelial cells. Ceria ENMs have
been seen in the cytoplasm of brain cells, phagosomes of macrophages, vesicles of
lung fibroblasts, spleen red pulp, Kupffer cells, hepatocytes and mesangial cells [18, 20,
38-41]. Thirty days after ceria ENM infusion the greatest concentration was seen in the
reticuloendothelial tissues, including liver and spleen [18, 20, 42]. It was reported that
lung, heart, and brain cerium did not decrease over 6 months following iv ceria ENM
dosing [39]. A study with the 30-nm ceria ENM used in the present study showed no
significant decrease of ceria in 14 tissues up to three months after iv administration. The
highest concentrations were in reticuloendothelial tissues (spleen, liver and bone
marrow), followed by the lung, then other sites [34]. We are not aware of any reports of

ceria uptake into red or white blood cells or platelets other than our prior finding
suggesting a small amount of a 30 nm ceria ENM might have entered red blood cells
after 1 h in vitro [18]. It is unclear if the ceria ENMs would ever reach a constant blood
level. Up to the times studied in the present report, there was generally a decrease of
blood cerium. Given the persistence of ceria in the rat, one might expect a steady state
to be reached. However, 90 days after ceria infusion blood cerium concentration was
higher than earlier times [34].

The cerium ion was equally distributed between serum and clot fractions. A previous
study reported that 2 h after iv cerium ion administration ~ 28% of the cerium in the
blood was in cells and 72% in serum [43], similar to results in the present study that
showed ~ 70% in the serum fraction at 2 h. The distribution of ceria ENMs between
serum and clot varied with size and surface chemistry. The 5-nm ceria was evenly
distributed within the serum and clot fractions. We previously observed small
agglomerations of the 5-nm ceria in serum, presumably associated with proteins, and
agglomerations associated with the extracellular side of the erythrocyte cell membrane
after 1 h of incubation of the ceria in blood [20]. The ability of ENMs to enter
erythrocytes, a non-phagocytic cell, has been observed for 78 nm polystyrene, 25-nm
gold, and 22-, 25- and 80-nm titania ENMs [44-46]. However, we are not aware of any
studies of ceria ENM or other metal/metal oxide ENMs entry into white blood cells or
platelets.

Although the extent of citrate coating might be expected to influence the fate of ceria
ENMs in vivo, the present results show no clear trends between the extent of citrate
surface coating and ceria ENM distribution between serum and the clot fraction initially,
or over time. For the cerium ion, and 5- and 55-nm and the mixture of 30-nm cubic +
rod ceria ENMs, we were unable to identify any trends in the percentage of Ce in the
serum vs. time.

The blood levels of the 15- and 30-nm ceria ENMs increased over the 4 h after their
infusion. As they were given by the iv route, this suggests a re-distribution of the ENM
over time. Redistribution of ENMs has been previously recognized and discussed, e.g.
[47]. An increase of ENM in blood within the first 2 h after iv administration has been
reported, although the increases appear to be within the variability of the reported
measure of the quantum dots in plasma or blood and neither report discusses the
increase [48, 49]. The increase we saw may be influenced by opsonization and/or
distribution into and out of a non-central compartment, such as the lymphatic system, as
noted by [50]. We also observed that the distribution of the 15- and 30-nm ceria ENMs
within blood compartments changed over the 4 h after completion of their infusion, when
they became more associated with the cells in the clot fraction. These results suggest
their surface chemistry changed during that period, which may be due to dissociation of
the citrate, association with proteins or blood cells, and/or cell entry and release.
Nanoscale materials are rapidly coated with plasma proteins and other circulating
substances, which create a corona around the ENM, increasing their hydrodynamic size
[51, 52]. It has been shown that citrate-coated ENMs bind to the surface of cells [24]

and can become opsonized with albumin [27]. We speculate that the increase of the
15- and 30-nm ceria ENMs in circulating blood and migration toward the clot fraction
during the first 4 h after their iv infusion is due to distribution out of, then back into,
circulating blood, perhaps associated with opsonization. This might be due to initial
accumulation in blood vessels or adsorption onto the luminal surface of vascular
endothelial cells, followed by opsonization and re-circulation in blood. However, we
would not anticipate extensive accumulations of ceria blocking the vasculature in the
absence of cardio- and cerebrovascular incident (MI and stroke) which we have not
observed in these rats that generally tolerated the target doses well. Or the ceria ENMs
may have distributed outside of the vascular compartment, such as entrapment by
reticuloendothelial organs followed by their release them back into blood, or entry into
the lymphatic system, that drains into the cardiovascular system. Particles up to 50 nm
are able to rapidly enter the lymphatic system [53, 54]. From the results of the present
study we do not have evidence of the origin of the ceria ENMs that re-entered
circulating blood during the first 4 h after their infusion. However, we have seen a net
migration of Ce following 30-nm ceria ENM administration from liver to spleen from 1 to
20 h after its infusion [55] and into lung over 90 days, consistent with re-distribution of
this ENM over time [34]. As > 98% of the ceria dose was no longer in circulating blood
when we started blood sampling 10 min after completion of the ceria infusion, the long
terminal half-life and MRT and large Vdss for the 5, 15 and 30 nm ceria ENMs, based on
blood levels to 30 days, may describe the very small fraction of the ENMs that had not
yet distributed out of blood and/or ceria re-distributing among storage sites. This
speculation is based on the retention of very large percentage of the ceria ENM dose for

a long time in the rat and evidence we (and others) have of re-distribution among sites
over time. Similarly, there may have been some re-distribution of the 5 nm ceria which
was not seen above the much higher level of ceria remaining in blood from the infusion
during the first 4 h after its infusion.

The non-compartmental analysis could not estimate some of the pharmacokinetic
parameters for the 15 and 30 nm ceria ENMs probably because of the ceria
concentration increase at the first 4 h. Due to the lack of prior studies of metal and
metal oxide ENMs in blood, further studies of citrate-coated ceria ENMs are necessary
to better understand their fate in the vascular compartment, including the stability of the
citrate coating; their interaction with cell membranes; and the rate, extent and character
of protein association.

The mean residence time (MRT) typically indicates the average time molecules stay in
the body. In our study, the MRT indicated how long ceria ENMs remained in blood, not
in the tissues, because MRT is derived from measurement of ceria (as Ce) in blood [56].
It has been previously noted that the blood half-life of an ENM may be short despite
prolonged body persistence, due to reticuloendothelial system entrapment and other
processes not typical of small inorganic and organic molecules [19]. Non-compartmental
and compartmental analyses produced quite different MRT results, although the trends
among the tested materials are similar across analysis. The lower MRT values with the
non-compartmental analysis may be due to its tendency to underestimate MRT [57].

Knowing that there are persistent accumulations of ceria ENMs in multiple organs
suggests the MRT results from the compartmental analysis more closely reflects the
whole body residence time of ceria ENMs. The results of the present pharmacokinetic
calculations that one can have the most confidence in are those obtained following
infusion of the cerium ion and the 5-nm ceria ENM, due to the very rapid clearance of
the larger ENMs from circulating blood and the rise in Ce concentration over 4 h
following 15- and 30-nm ceria ENM infusion. Although the results obtained with the
cerium ion and 5, 15 and 30 nm ceria ENMs clearly show two compartments, the values
for the second compartment do not have a high degree of precision due to the limited
number of data points on which they are based.

It has been previously noted that some of the properties of ENMs, e.g., opsonization,
adhesion, and phagocytic uptake, may differ from small organic molecule disposition for
which pharmacokinetic modeling programs such as WinNonLin were created [19].
Pharmacokinetic and PBPK approaches have been used to model ENM distribution
among tissues and blood [58, 59]. Most nanomaterials do not exhibit ADME profiles
typical of drugs [60], e.g. they are rapidly cleared from the blood, not metabolized, and
not rapidly eliminated, unless small enough to be filtered by the renal glomerulus. It has
been recognized that the toxicokinetics of ENMs are unlikely to follow the “rules” of
current approaches [61, 62]. Further work is needed to develop a pharmacokinetic
model to predict the time-dependent changes of ceria ENM distribution in tissues and
blood.

There is considerable literature on the pharmacokinetics of polymer ENMs due to the
extensive research in developing them as drug delivery systems. Much less is known
about the pharmacokinetics of metal and metal oxide ENMs; particularly their
distribution, residence time, and rate of clearance from the vascular compartment. The
present study informs about the effects of ENM physicochemical properties on
distribution and clearance from blood. The results show ceria ENMs have a
biodistribution and clearance pattern which cannot be predicted from the cerium ion.
This may be due to the very different physicochemical properties of the cerium ion and
ceria ENMs.

Conclusions:
To better understand the fate of ceria as a model ENM we compared the distribution
within, and rate of clearance from, blood of four different sizes of cubic or polyhedral
ceria nanoparticles, a mixture of cubes and rods, and the cerium ion after iv infusion into
rats. Table 3 summarizes the main findings of the present study. The kinetics and
distribution of the cerium ion did not predict those of the ceria ENMs. A 5-nm ceria
ENM, which was very resistant to agglomeration and settling in vitro, was cleared much
more slowly from blood than larger ceria ENMs, presumably because it was too large to
be cleared by glomerular filtration and perhaps too small or too hydrophilic to be readily
recognized by the reticuloendothelial system. Ceria ENMs larger than 5 nm were very
rapidly cleared from circulating blood. All the ceria ENMs had a much greater Vdss than
the cerium ion, consistent with their extensive distribution and prolonged retention
throughout the rat. The 15 and 30 nm ceria ENMs showed concentration ratios
increasing vs. cerium ion over 4 h after infusion. The distribution of ceria ENMs

between serum and the blood clot was size dependent. The citrate-coated 30-nm ceria
showed the greatest distribution in the clot fraction. The fraction of 15 and 30 nm-ceria
ENMs in the clot fraction increased over 4 h, suggesting a change in their surface
properties, perhaps due to opsonization. A further understanding of the rate and nature
of ceria ENM association with blood proteins and cells, and the process(es) of their
clearance from blood, is needed to fully interpret their fate in the vascular compartment.
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Figure legends.
Figure 1. HRTEM and STEM images of ceria used in this study: (a) TEM/STEM: 5-nm
polyhedral ceria; (b) TEM: 15-nm polyhedral ceria; (c) TEM: 30-nm cubic ceria; (d) TEM:
30-nm cubic and rod ceria; (e) STEM: 55-nm polyhedral ceria.

Figure 2. Whole blood Ce concentration after completion of iv infusion of the cerium ion,
5, 15, and 30 ceria ENM, a mixture of 30-nm ceria cubes and rods, and 55-nm ceria
ENM. All values are normalized to an equivalent dose of 100 mg ceria/kg. Results are
mean ± S.D. from 5 rats at each time point, except for cerium ion, where n = 3 for 5 nm
ceria ENM where n = 9, 10, 21, 10, 12, and 7 rats at 0.167, 0.5, 1, 2, 20 and 720 h; for
15 nm ceria ENM where n = 10 rats at 0.167, 0.5, 1, 2, and 4 h; for 30 nm ceria ENM
were n = 6 for al times except 1, 20 168 and 720 h where n = 10, 8, 3 and 11; and for
the 55 nm ceria ENM were n = 10 and 7 at 1 and 20 h, respectively. The horizontal line
at the top of each graph shows the calculated cerium concentration in blood
representing 100% of the dose.

Figure 3. The ratio of Ce concentration in whole blood following iv infusion of 5-, 15-, 30and 55-nm ceria ENMs from 0.167 to 4 h after their infusion, compared to the cerum ion
concentration. Each symbol represents a different rat.

Figure 4. The ratio of cerium in serum to whole blood (as %), following iv infusion of the
cerium ion; 5-, 15-, and 30-nm ceria ENMs; mixture of 30-nm cubic + rod ceria ENMs;
and 55-nm ceria ENM. Each symbol shows results from a different rat. For the 15-nm
ceria ENM the solid curve is the model for the rat shown by the open circle, dashed line

for rat shown by the closed square, and double curve for rat shown by the closed
diamond. For the 30-nm ceria ENM the solid curve is the model for the rat shown by the
closed square, dashed line for rat shown by the open circle, double curve for rat shown
by the closed diamond, and long dash dot curve for rat shown by the open triangle.
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Table 1. Physico-chemical properties of the ceria ENMs. Shape delineation based on
TEM data. Dave (average primary particle diameter from number frequency distribution)
and standard deviation based on TEM measurements of diameter fitted using lognormal
distribution models. Citrate loading expressed as % of monolayer coverage (TGA
analysis).

zeta potential
in water at
pH~ 7.3 (mV)

extent of
surface citrate
coating

polyhedral

Dave, nm
(st. dev.)
[TEM, Lognormal model]
4.6 (0.135)

- 53 ± 7

~ 40%

15

polyhedral

12.0 (0.232)

- 57 ± 5

~ 27%

30

cubic

31.2 (0.478)

- 56 ± 8

~ 18%

55

polyhedral

55 (0.162)

- 32 ± 2*

~ 15%*

Ceria ENM
primary
size(nm)

shape

5

* Determinations made on a batch similarly-prepared to that administered to the rats.

Table 2. Pharmacokinetic parameters for the cerium ion; 5-, 15-, 30- and 55-nm ceria ENMs; and mixture of 30-nm cubic
and rod ceria ENMs and after iv infusion to rats. Values are means ± SD, calculated from results obtained from times
shown (after completion of the infusion).
0.167 h to 7 days
Parameter

cerium ion (n=3)

0.167 h to 30 days
5-nm ceria
(n=3)

15-nm ceria
(n=4)

0.167 to 4 h
30-nm cubic
ceria (n=5)

30-nm cubic +
rods ceria (n=5)

55 nm ceria
(n=5)

25 ± 8a
20 ± 11a
26 ± 36a
1.6 ± 1.8a

1.5 ± 0.5a
0.78 ± 0.12a
2.2 ± 0.8a
1.5 ± 0.1a

Non-compartmental Analysis
AUC (h* mg/L)
Cmax (mg/L)
t1/2 (h)
MRT (h)

102a

326 ±
163 ± 27a
2.7 ± 0.8a
1.5 ± 0.2a

2264 ± 1284b
278 ± 215b
80 ± 25b
7.1 ± 3.0a

361 ± 130a
0.95 ± 0.34a
41 ± 11b

2201 ± 1314b
6.5 ± 3.1a
15 ± 11a

Two Compartment Model

One Compartment Model

AUC (h* mg/L)
1377 ± 416c
690 ± 181a
152 ± 41b
561 ± 256a
72 ± 39b
1.9 ± 0.7b
Cmax (mg/L)
190 ± 29a,b
372 ± 317a
0.82 ± 0.45b
3.5 ± 1.7b
12 ± 5b
0.88 ± 0.44b
t1/2-α (h)
0.57 ± 0.13
0.44 ± 0.27
2.5 ± 2.6
12 ± 17
4.3 ± 1.8
1.9 ± 0.6
b
a,b
c
a
t1/2-β (h)
16 ± 3
124 ± 53
239 ± 56
140 ± 43
c
a,c
b
a
c
MRT (h)
21 ± 3
92 ± 53
343 ± 83
192 ± 57
6.3 ± 2.6
2.8 ± 0.8c
a
a
a
a
a
CL (L/h/kg)
0.078 ± 0.028
0.15 ± 0.04
0.71 ± 0.24
0.22 ± 0.11
1.4 ± 1.0
46 ± 30b
Vdss (L/kg)
1.7 ± 0.8a
15 ± 12a
240 ± 8b
38 ± 12a
9.6 ± 3.9a
130 ± 42c
AUC, area under the concentration–time curve; t1/2-α , first half-life; t1/2-β , second half-life; Cmax, peak concentration; CL,
Clearance; MRT, mean residence time; Vdss, volume of distribution at steady state.
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*

For each parameter, results that do not have the same superscript letters are statistically significantly different by post
hoc test (p < 0.05 ).

57

Table 3. The whole blood compartment model, serum and clot partitioning, and ceria
ENM vs. cerium ion ratio results of the six materials studied.
[Ce]ceria
[Ce]cerium(ion )

Serum/whole
blood
partitioning

Material

Compartment modeling

R=

Cerium ion

Fits the two compartment
model

Not applicable

No strong
trend

5 nm ceria

Fits the two compartment
model; longer persistence in
the second compartment than
the cerium ion

Time-dependent
reduction in [Ce]
relative to the ion;
1st order or other
process possible

No strong
trend

Increase relative to
[Ce]ion; 1st order
process

Reduction in
serum levels
with time; 1st
order process
(opsonization
?)

Increase relative to
[Ce]ion; 1st order
process

Reduction in
serum levels
with time; 1st
order process
(opsonization
?)

15 nm ceria

Rapid loss during infusion;
Apparent re-distribution to
blood in 2-4 hours

30 nm ceria

Rapid loss during infusion;
Apparent re-distribution to
blood in 2-4 hours

Cubic + rod ceria

Loss during infusion;
Apparent redistribution to
blood in 2-4 hours

No strong trend

No strong
trend; less
than 50% in
serum

55 nm ceria

Rapid loss during infusion; No
apparent re-distribution to
whole blood in 2-4 hours

No strong trend

No strong
trend

58

